[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thyroid-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thyroid-carcinoma":47},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,92,114,140,167,189,219,260,282,342,364,393],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":59,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":91},"100499720","phase-1-phase-12-trial-of-s241656-in-selected-rasmapk-mutation--positive-malignancies-100499720",false,"NCT05786924","Phase 1\u002F2 Trial of S241656 in Selected RAS\u002FMAPK Mutation- Positive Malignancies","A Phase 1\u002F2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With KRAS, BRAF and Other Selected RAS\u002FMAPK Mutation-Positive Malignancies","Key Inclusion Criteria:\n\n* Life expectancy of ≥ 12 weeks in the opinion of the investigator.\n* Histologically or cytologically confirmed recurrent locally advanced (unresectable) or metastatic solid tumors with documented RAS or RAF mutations or alterations.\n* Adequate bone marrow and organ function.\n* Recovered from toxicity to prior anti-cancer therapy.\n\nPart 1 Dose Escalation cohort ONLY:\n\n* Part 1A: Advanced\u002Fmetastatic NSCLC with KRAS non-G12C, HRAS, NRAS, BRAF or CRAF (RAF1) mutations or alterations\n* Part 1B: Advanced\u002Fmetastatic GI tumors (e.g., PDAC, CRC, and BTC) with KRAS, HRAS, NRAS, BRAF, and\u002For CRAF (RAF1) mutations or alterations\n* Part 1C: Advanced\u002Fmetastatic PDAC with KRAS, HRAS, NRAS, BRAF, and\u002For CRAF (RAF1) mutations or alterations\n* Part 1D: Colorectal adenocarcinoma with KRAS, HRAS, NRAS, BRAF, and\u002For CRAF (RAF1) mutations or alterations\n* Part 1E: Other advanced\u002Fmetastatic non-GI, non-NSCLC solid tumors with KRAS, HRAS, NRAS, BRAF, CRAF (RAF1) mutations or alterations\n\nPart 2 Dose Optimization and Expansion cohorts ONLY:\n\n* Part 2A: Advanced\u002Fmetastatic NSCLC with KRAS non-G12C mutations and\u002For BRAF mutations\n* Part 2A1: Advanced\u002Fmetastatic NSCLC with KRAS non-G12C mutations\n* Part 2A2: Advanced\u002Fmetastatic NSCLC with BRAF mutations\n* Part 2A3: Advanced\u002Fmetastatic NSCLC with KRAS non-G12C or BRAF mutations or alterations and active CNS metastatic disease\n* Part 2A4: Advanced\u002Fmetastatic NSCLC with a KRAS G12C mutation\n* Part 2B1: Advanced\u002Fmetastatic PDAC with KRAS, HRAS, NRAS, BRAF, and\u002For CRAF (RAF1) mutations or alterations\n* Part 2B2: Advanced\u002Fmetastatic CRC with KRAS, HRAS, NRAS, BRAF, and\u002For CRAF (RAF1) mutations or alterations\n* Part 2B3: Advanced\u002Fmetastatic BTC (adenocarcinoma) with KRAS, HRAS, NRAS, BRAF, and\u002For CRAF (RAF1) mutations or alterations\n\nKey Exclusion Criteria:\n\n* Cancer that has a known MEK1\u002F2 mutation.\n* Known allergy\u002Fhypersensitivity to excipients of S241656 or to any of the registered IMPs administered in combination.\n* Any contra-indication, to use of any of the combination chemotherapy or anti-EGFR therapy partners administered as part of this trial.\n* Major surgery within 4 weeks of study entry or planned during study.\n* Ongoing anticancer therapy.\n* Ongoing radiation therapy.\n* Uncontrolled or active clinically relevant bacterial, fungal, or specific viral infection requiring systemic therapy.\n* Clinically significant cardiovascular disease.\n* Symptomatic spinal cord compression.\n* Evidence of active malignancy (other than study-specific malignancies) requiring systemic therapy within the next 2 years.\n* History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO.\n* Females who are pregnant or breastfeeding.\n* Actively receiving systemic treatment or direct medical intervention on another therapeutic clinical study.\n* Prior use of experimental agents that target the KRAS\u002FBRAF\u002FMEK\u002FERK pathway.","ALL","18 Years",{"count":19,"type":20},554,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","BDTX-4933-101 is a first-in-human, open-label, Phase 1\u002F2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies in participants with selected advanced malignancies. The study population for the Dose Escalation part of the study comprises adults with recurrent advanced\u002Fmetastatic non-small cell lung cancer (NSCLC), Gastrointestinal (GI) cancers, and other solid tumors harboring KRAS, HRAS, NRAS, BRAF, and\u002For CRAF (Rapidly Accelerated Fibrosarcoma (RAF1)) mutations or alterations. A dose optimization part in adults with NSCLC may follow the dose escalation phase if the sponsor, in consultation with the safety review committee, decides it is necessary to further characterize the optimal dose. However, the study may also proceed directly to the expansion phase. The study population for the Dose Expansion part of the study comprises adults with advanced\u002Fmetastatic NSCLC with KRAS and\u002For BRAF mutations, and with Pancreatic Ductal AdenoCarcinoma (PDAC), ColoRectal Cancer (CRC), and Biliary Tract Cancer (BTC) with KRAS, HRAS, NRAS, BRAF, and\u002For CRAF (RAF1) mutations and alterations. All patients will self-administer S241656 orally in 28-day cycles until disease progression, toxicity, withdrawal of consent, or termination of the study.",[27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58],"Non-small Cell Lung Cancer","Histiocytic Neoplasm","Histiocytosis","BRAF Gene Mutation","BRAF V600E","BRAF V600 Mutation","BRAF Mutation-Related Tumors","BRAF","Metastatic Lung Non-Small Cell Carcinoma","Metastatic Lung Cancer","Recurrent Lung Cancer","Recurrent Lung Non-Small Cell Carcinoma","NSCLC","Solid Tumor","Solid Carcinoma","KRAS G12D","KRAS G12V","KRAS Mutation-Related Tumors","NRAS Gene Mutation","Thyroid Cancer","Thyroid Carcinoma","Colorectal Cancer","Colorectal Carcinoma","Recurrent Histiocytic and Dendritic Cell Neoplasm","Brain Metastases","Recurrent NSCLC","KRAS G13C","Acquired Resistance to KRAS G12C Inhibitor","KRAS G12A","KRAS G12F","KRAS G12R","KRAS G13D",[60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78],"BRAF Class I","BRAF Class II","BRAF Class III","KRAS","Intolerant histiocytic neoplasm","BDTX-4933","Phase 1","dose escalation","dose expansion","MAPK","mitogen-activated protein kinase","RAS","RAF","Upstream oncogenic alterations","RAF inhibitor","intracranial disease","CRAF","NRAS","RAF fusions","RECRUITING","2026-06-16",{"date":82,"type":83},"2026-06-17","ACTUAL",{"date":85,"type":83},"2023-04-18",{"date":87,"type":20},"2028-06",{"name":89,"class":90},"Institut de Recherches Internationales Servier","OTHER",27,{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":21,"phases":100,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":113},"100609725","nanosecond-pulsed-field-ablation-in-the-management-of-t1n0m0-papillary-thyroid-carcinoma-100609725","NCT07218315","Nanosecond Pulsed Field Ablation in the Management of T1N0M0 Papillary Thyroid Carcinoma","Inclusion Criteria:\n\n* Participant must provide voluntary, written informed consent to participate in this clinical investigation.\n* Participant agrees to comply with all study procedures, including all follow-up visits.\n* Participant with a Bethesda VI cytology (tumor size \\\u003C= 1.5 cm, no known regional\u002Fdistant metastases)\n* Participant with a Bethesda V cytology and normal calcitonin levels.\n* Ultrasonographic evaluation of tumor to be ablated must show size of less than or equal to 1.5 cm and no extrathyroidal extension or locoregional metastases.\n* Participant must have normal complete blood count, blood coagulation profile, and thyroid function test.\n* For females of childbearing potential, a negative serum or urine pregnancy test must be obtained at baseline, prior to the procedure.\n* Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. (Refer to Pregnancy Assessment Policy MD Anderson Institutional Policy # CLN1114). This includes all female patients, between the onset of menses (as early as 8 years of age) and 55 years unless the patient presents with an applicable exclusionary factor which may be one of the following: ). This includes all female patients, between the onset of menses (as early as 8 years of age) and 55 years unless the patient presents with an applicable exclusionary factor which may be one of the following:\n\n  * Postmenopausal (no menses in greater than or equal to 12 consecutive months).\n  * History of hysterectomy or bilateral salpingo-oophorectomy.\n  * Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy).\n  * History of bilateral tubal ligation or another surgical sterilization procedure.\n* Approved methods of birth control are as follows: Hormonal contraception (i.e. birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject\u002FPartner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.\n* Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of study procedure.\n\nExclusion Criteria:\n\n* FNA findings suggestive of high-grade malignancy\n* Presence of regional or distant lymph node metastases.\n* Participant had a history of previous neck irradiation.\n* Females who are pregnant at time of enrollment.\n* Participant has any condition or situation, in the opinion of the site Investigator, that puts the subject at significant risk, could confound the study results, or may interfere significantly with subject's participation in the study.",{"count":99,"type":20},15,[101],"NA","This study is to evaluate the effectiveness of nsPFA in treating papillary thyroid microcarcinoma. T",[47],"2026-05-29",{"date":106,"type":83},"2026-06-02",{"date":108,"type":83},"2026-02-11",{"date":110,"type":20},"2031-01-31",{"name":112,"class":90},"M.D. Anderson Cancer Center",2,{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":21,"phases":122,"briefSummary":123,"conditions":124,"keywords":126,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":139},"100335433","phase-1-lesion-dosimetry-with-iodine-124-in-metastatic-thyroid-carcinoma-100335433","NCT03647358","Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma","Inclusion Criteria:\n\n* Adults with thyroid carcinoma confirmed by pathology.\n* Adult thyroid carcinoma patients who have undergone total thyroidectomy\n* Adult thyroid carcinoma patients have metastatic disease or suspicion for metastatic disease, or are under a protocol intended to explore re-induction therapy for 131I uptake, and are about to undergo Thyrogen-assisted dosimetry, unless Thyrogen-assisted dosimetry is not required per standard of care.\n* The patient and physician are planning to administer 131I for therapy if persistent radioiodine-avid metastases are present.\n* All subjects must have measurable disease, documented within the previous six months by ultrasonography (US), MRI, FDG PET\u002FCT, or CT scanning.\n\nExclusion Criteria:\n\n* Age less than 18 years.\n* Patients who are pregnant.",{"count":121,"type":20},60,[23],"The purpose of this study is to evaluate a new diagnostic imaging test, positron emission tomography (PET), with a different radioactive form of iodine called iodine-124. This form is able to accurately measure the amount of radioactive iodine uptake in the cancer. If the new test determines sufficient radioiodine uptake in the cancer, treatment will continue as usual. However, if the new test shows only low radioiodine uptake, a decision may be made that the benefit from radioiodine therapy is insufficient and that another form of therapy is preferred.",[47,125],"Metastatic Thyroid Carcinoma",[127,128,129],"Iodine-124","PET Scan","18-253","2026-04-13",{"date":132,"type":83},"2026-04-14",{"date":134,"type":83},"2018-08-21",{"date":136,"type":20},"2027-08",{"name":138,"class":90},"Memorial Sloan Kettering Cancer Center",1,{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":149,"phases":4,"briefSummary":150,"conditions":151,"keywords":153,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":139},"100527361","ceus-improves-the-diagnostic-performance-of-srss-of-thyroid-carcinoma-100527361","NCT06146764","CEUS Improves the Diagnostic Performance of SRSS of Thyroid Carcinoma","Contrast-enhanced Ultrasound Improves the Diagnostic Performance of Sonographic Risk Stratification System of Thyroid Carcinoma: Comparison Between Integrated Scoring Method and Up-and-down Scoring Method","Inclusion Criteria:\n\n* Participants with thyroid nodules with a solid component ≥5 mm confirmed by conventional ultrasound;\n* Participants who underwent conventional ultrasound, contrast-enhanced ultrasound, and fine-needle aspiration biopsy;\n* Participants with a final benign or malignant pathological results.\n\nExclusion Criteria:\n\n* Participants with cytopathology of Bethesda I, III, or IV and without final benign or malignant pathology；\n* Participants with a history of thyroid ablation or surgery;\n* Participants with low-quality ultrasound images.",{"count":148,"type":20},800,"OBSERVATIONAL","Contrast-enhanced ultrasound (CEUS) can sensitively show the blood perfusion characteristics of thyroid nodules, which is a useful supplement to gray-scale ultrasound. However, there is no standard combined diagnostic method of gray-scale ultrasound and CEUS. Therefore, the aim of this study was to compare the diagnostic performance of the integrated scoring method and the up-and-down scoring method. This study was a multicenter retrospective clinical study and followed the Standards for Reporting of Diagnostic Accuracy Studies (version 2015). Inclusion criteria: 1) participants with at least one thyroid nodule larger than 5 mm confirmed by conventional ultrasound; 2) participants underwent gray-scale ultrasound, contrast-enhanced ultrasound and fine needle aspiration biopsy of the thyroid nodule successively; 3) participants have a final diagnosis of benign or malignant. Exclusion criteria included: 1) participants with cytologic findings of Bethesda I, III, or IV without definitive benign or malignant pathologic findings; 2) participants with a history of thyroid fine needle aspiration, ablation or surgery; 3) participants with low quality ultrasound images (e.g., severe artifacts or low image resolution). According to the American College of Radiology Thyroid Imaging Reporting and Data System, only one thyroid nodule with the highest point was included in each participant. A total of 600 participants from January 2018 to December 2022 were consecutively included in Sun Yat-sen Memorial Hospital of Sun Yat-sen University to form a training set (average age 48 years; Range 24-81 years old). A total of 200 subjects with thyroid nodules from January 2022 to December 2022 were consecutively included to form an external validation set in Houjie Hospital of Dongguan City, Guangdong Province (mean age 46 years; Range 30-74 years). The malignant risk of enrolled thyroid nodules and the necessity of biopsy were evaluated by integrated scoring method and up-and-down scoring method, respectively. The diagnostic performance and unnecessary biopsy rate of the above two methods were calculated and compared.",[152,47],"Thyroid Nodule",[152,154,155,156,157],"Contrast Media","Gray-scale Ultrasound","Diagnosis","Biopsy","2026-03-18",{"date":160,"type":83},"2026-03-23",{"date":162,"type":83},"2023-03-18",{"date":164,"type":20},"2026-07-31",{"name":166,"class":90},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University",{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":16,"minAge":173,"maxAge":174,"enrollmentInfo":175,"targetDuration":4,"studyType":149,"phases":4,"briefSummary":177,"conditions":178,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":113},"100629349","thyroid-carcinoma-in-cancer-patients-undergoing-radiotherapy-100629349","NCT07473518","Thyroid Carcinoma in Cancer Patients Undergoing Radiotherapy","INCLUSION CRITERIA\n\nFor the group of oncologic patients who underwent radiotherapy:\n\n* Radiotherapy for an oncologic condition performed between January 1, 1999, and December 31, 2018;\n* Age at the time of radiotherapy \\\u003C 18 years;\n* Follow-up of at least 4 years conducted at the Endocrine-Metabolic Diseases Program, Pediatric Unit, IRCCS AOU Bologna;\n* Obtained informed consent\n\nFor the group of subjects not exposed to radiotherapy and without specific risk factors for DTC:\n\n* No history of exposure to ionizing radiation;\n* No specific risk factors for DTC (autoimmune thyroiditis, familial forms, genetic syndromes);\n* Thyroid ultrasound performed between January 1, 1999, and December 31, 2018, at the Nuclear Medicine Unit of IRCCS AOU Bologna;\n* Age at the time of the thyroid ultrasound \\\u003C 18 years;\n* Obtained informed consent\n\nEXCLUSION CRITERIA:\n\nFor the group of oncologic patients who underwent radiotherapy:\n\n* Patients transferred to another center before completing 4 years of follow-up after radiotherapy at the Pediatric Unit of IRCCS AOU Bologna, without having received a diagnosis of thyroid cancer.\n\nFor the group of subjects not exposed to radiotherapy and without specific risk factors for DTC:\n\n* None.","10 Years","43 Years",{"count":176,"type":20},2550,"This study aims to define the optimal surveillance strategy for children exposed to radiotherapy by assessing the incidence, risk factors, and timing of thyroid nodules and differentiated thyroid cancer. It also investigates the genetic features of thyroid tumors in this population to identify predictive biomarkers of onset, malignancy, and aggressiveness. Ultimately, the goal is to support more personalized management, including tailored surgery and targeted therapies.",[47,179],"Pediatric Cancer","2026-03-11",{"date":182,"type":83},"2026-03-16",{"date":184,"type":83},"2025-07-30",{"date":186,"type":20},"2027-07-30",{"name":188,"class":90},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":149,"phases":4,"briefSummary":198,"conditions":199,"keywords":205,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":113},"100620589","laryngopharyngeal-injury-after-endotracheal-intubation-under-general-anesthesia-100620589","NCT07359586","Laryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia","Incidence,Perioperative Risk Factors and Prognosis Associated With Laryngopharyngea Injury After Endotracheal Intubation Under General Anesthesia：A Retrospective Study","Inclusion Criteria:\n\n* Patients who underwent general anesthesia with tracheal intubation at the First Affiliated Hospital of Zhejiang University School of Medicine between October 2015 and September 2025\n* Patients who required otolaryngological consultation due to laryngopharyngeal complaints (including hoarseness, sore throat, cough, choking on drinking water, etc.) postoperatively\n* The surgical type was non-otolaryngological surgery\n\nExclusion Criteria:\n\n* Patients with a history of laryngopharyngeal lesions (e.g., granuloma, polyp, tumour, vocal cord paralysis\n* Patients with a preexisting tracheotomy\n* Patients requiring postoperative tracheotomy\n* Patients with incomplete medical records\n* Patients who underwent multiple surgeries but for whom the specific surgical episode responsible for the laryngopharyngeal complaints could not be identified",{"count":197,"type":20},1200,"This study retrospectively analyzed patients who underwent tracheal intubation under general anesthesia at the First Affiliated Hospital of Zhejiang University School of Medicine between October 1, 2015, and September 30, 2025, with a focus on issues related to postoperativelaryngopharyngeal complaints. Patients requiring otolaryngological consultation due to postoperative laryngopharyngeal complaints were identified via the case consultation system. Relevant patient data were collected through the Medison Anesthesia Information Management System and electronic medical record system, and telephone follow-up was conducted to assess patient prognosis. The primary outcome measures were the risk factors of postoperative hoarseness, while the secondary outcome measures included the incidence of postoperative hoarseness, the severity of vocal fold injury and its related risk factors. Additionally, the prognosis of patients and its related risk factors were evaluated. This study aims to reduce the incidence of perioperative laryngopharyngeal injury and provide a reference for the optimization of perioperative anesthetic regimens.",[200,201,202,203,204,47],"Gastric Cancer","Hepatic Carcinoma","Pulmonary Carcinoma","Pancreatic Carcinoma","Cholangiocarcinoma",[206,207,208,209],"hoarseness","Vocal cord injury","Incidence","Prognosis","2026-01-13",{"date":212,"type":83},"2026-01-22",{"date":214,"type":83},"2025-11-01",{"date":216,"type":20},"2026-12-25",{"name":218,"class":90},"Zhejiang University",{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":225,"eligibilityCriteria":226,"healthyVolunteers":11,"sex":16,"minAge":227,"maxAge":17,"enrollmentInfo":228,"targetDuration":4,"studyType":149,"phases":4,"briefSummary":230,"conditions":231,"keywords":245,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":139},"100598488","an-international-study-on-pediatric-patients-with-rare-tumors-100598488","NCT07072143","An International Study on Pediatric Patients With Rare Tumors.","The PARTNER Study - An International Prospective Observational Study on Pediatric Patients With Very Rare Tumors.","PARTNER","Inclusion Criteria:\n\n* Children and adolescents (age 0-18 years) with a primary or relapsed Very Rare Tumor diagnosed and\u002For treated in a participating country\u002Fcenter.\n* Written informed consent from the patient and\u002For the parent\u002Flegal guardian\n\nExclusion Criteria:\n\n* Absence of Written informed consent from the patient and\u002For the parent\u002Flegal guardian","0 Years",{"count":229,"type":20},6250,"The PARTNER study is an international, prospective, observational study of paediatric patients with very rare tumours.",[232,233,234,235,236,237,238,239,240,241,242,243,47,244],"Paraganglioma\u002F Phaeochromocytoma","Melanoma and Other Malignant Neoplasms of Skin","Gastrointestinal Stromal Tumor (GIST)","Adrenocortical Tumor","Pancreatic Tumors","Esthesioneuroblastoma, Olfactory","Mesothelioma","Nasopharyngeal Carcinoma (NPC)","NUT Carcinoma","Pleuropulmonary Blastoma","Salivary Gland Tumors","Thymic Tumors","Appendiceal Cancers",[246,247,248,249,250],"children","rare tumors","very rare tumors","adolescents","PARTNER Study","2025-07-16",{"date":253,"type":83},"2025-07-18",{"date":255,"type":83},"2025-01-25",{"date":257,"type":20},"2049-06-06",{"name":259,"class":90},"Azienda Ospedaliera di Padova",{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":264,"acronym":4,"eligibilityCriteria":265,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":266,"targetDuration":4,"studyType":149,"phases":4,"briefSummary":268,"conditions":269,"keywords":270,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":139},"100582476","evaluation-of-the-clinical-utility-of-circulating-biomarkers-in-advanced-thyroid-carcinomas-100582476","NCT06863805","Evaluation of the Clinical Utility of Circulating Biomarkers in Advanced Thyroid Carcinomas","Inclusion Criteria:\n\n* Signed written informed consent,\n* Adult (≥18 years) male or female patients\n* Histologic diagnosis of advanced thyroid carcinoma confirmed at centralized review,\n* well-differentiated thyroid carcinomas, medullary thyroid carcinomas, anaplastic thyroid carcinomas, advanced, candidates for initiation of systemic medical therapy,\n* Availability of biomolecular profiling performed by multigenic NGS panel on tumor tissue,\n* Measurable disease by conventional imaging adopted in clinical practice (total body CT with mdc, CT-PET with FDG or F-DOPA).\n\nExclusion Criteria:\n\n* Patients already receiving previous lines of systemic therapy,\n* Patients not eligible for systemic therapy.",{"count":267,"type":20},10,"The study is aimed at all adult patients diagnosed with advanced thyroid carcinomas and well-differentiated thyroid carcinomas (DTC) iodine-refractory, well-differentiated iodine-refractory thyroid (RAI-R DTC) metastatic carcinomas that are candidates for systemic therapy. By simple blood sampling and analysis on peripheral blood of circulating DNA (ccf-DNA), circulating RNA (ccf-RNA), and counting and analysis of circulating tumor cells through the use of liquid biopsy, molecular profiling corresponding to those obtained by genomic sequencing on tumor tissue can be arrived at, depending on optimal therapeutic choices",[47],[271,272,273],"carcinomas of thyroid","molecular markers","liquid biopsy","2025-03-03",{"date":276,"type":83},"2025-03-07",{"date":278,"type":83},"2022-12-15",{"date":280,"type":20},"2027-12-31",{"name":188,"class":90},{"id":283,"slug":284,"hasResults":11,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":4,"eligibilityCriteria":288,"healthyVolunteers":289,"sex":16,"minAge":290,"maxAge":291,"enrollmentInfo":292,"targetDuration":173,"studyType":149,"phases":4,"briefSummary":294,"conditions":295,"keywords":313,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":139},"100315102","international-ppbdicer1-registry-100315102","NCT03382158","International PPB\u002FDICER1 Registry","International Pleuropulmonary Blastoma\u002FDICER1 Registry (for PPB, DICER1 and Associated Conditions)","Inclusion Criteria:\n\n1. Known or suspected PPB or related thoracic tumor\n2. Known or suspected sex-cord stromal tumor including Sertoli-Leydig cell tumor and gynandroblastoma (males or females)\n3. Other known or suspected DICER1-related condition including ovarian sarcoma, cystic nephroma, renal sarcoma, pineoblastoma, pituitary blastoma, nasal chondromesenchymal hamartoma, ciliary body medulloepithelioma and others\n4. Individuals with known or suspected DICER1 pathogenic variation regardless of whether they have an established DICER1-associated condition\n5. Informed consent by patient\u002F or parent\u002Fguardian (also, where appropriate: assent and HIPAA consent)\n\nExclusion criteria:\n\nAbsence of appropriate consent for Registry participation",true,"0 Minutes","100 Years",{"count":293,"type":20},3400,"Pleuropulmonary blastoma (PPB) is a rare malignant neoplasm of the lung presenting in early childhood. Type I PPB is a purely cystic lesion, Type II is a partially cystic, partially solid tumor, Type III is a completely solid tumor. Treatment of children with PPB is at the discretion of the treating institution. This study builds off of the 2009 study and will also seek to enroll individuals with DICER1-associated conditions, some of whom may present only with the DICER1 gene mutation, which will help the Registry understand how these tumors and conditions develop, their clinical course and the most effective treatments.",[241,296,297,298,299,300,301,302,303,304,305,306,307,308,309,47,310,311,312],"Sertoli-Leydig Cell Tumor","DICER1 Syndrome","Cystic Nephroma","Wilms Tumor","Pineoblastoma","Renal Sarcoma","Nodular Hyperplasia of Thyroid","Nasal Chondromesenchymal Hamartoma","Ciliary Body Medulloepithelioma","Neuroblastoma","Pituitary Cancer","Embryonal Rhabdomyosarcoma","Ovarian Sarcoma","Gynandroblastoma","Embryonal Rhabdomyosarcoma of Vagina (Diagnosis)","Embryonal Rhabdomyosarcoma of Uterus (Diagnosis)","Embryonal Rhabdomyosarcoma of Cervix",[314,315,316,317,296,298,318,319,320,299,300,301,321,302,322,47,303,323,304,324,305,306,307,325,308,309,326,327,328,329,330,331,332],"pleuropulmonary blastoma","PPB","DICER1","SLCT","CN","DICER1 mutation","DICER1 syndrome","ASK","Thyroid Nodules","NCMH","CBME","ERMS","Peritoneal PPB","pPPB","multinodular goiter","PPB Type I","PPB Type II","PPB Type III","PPB Type Ir","2025-01-28",{"date":335,"type":83},"2025-01-30",{"date":337,"type":83},"2016-12-06",{"date":339,"type":20},"2035-12-06",{"name":341,"class":90},"Children's Hospitals and Clinics of Minnesota",{"id":343,"slug":344,"hasResults":11,"nctId":345,"briefTitle":346,"officialTitle":346,"acronym":4,"eligibilityCriteria":347,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":348,"targetDuration":350,"studyType":149,"phases":4,"briefSummary":351,"conditions":352,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":139},"100576012","evaluation-of-different-diagnostic-therapeutic-strategies-in-patients-with-thyroid-pathology-100576012","NCT06779747","Evaluation of Different Diagnostic Therapeutic Strategies in Patients with Thyroid Pathology","Inclusion Criteria:\n\n* Age older than 18 years at the time of diagnosis;\n* Patients with thyroid pathology (hypothyroidism, hyperthyroidism\u002Fthyrotoxicosis, benign thyroid nodule, and thyroid carcinoma) in whom the diagnosis was made in our Center or another Center from 01\u002F01\u002F1995 until the approval of this study (retrospective phase) or from the time of approval of this study to the next 10 years (prospective phase);\n* Obtaining informed consent.\n\nExclusion Criteria:\n\n* Follow up lasting less than 3 months;\n* Incomplete or missing clinical data that may affect the correct assessment of the patient.",{"count":349,"type":20},5850,"20 Years","Observational single-center prospective and retrospective, nonpharmacological, spontaneous cohort study.",[353,354,355,47],"Hypothyroidism","Hyperthyroidism\u002FThyrotoxicosis","Thyroid Nodule (Benign)","2025-01-13",{"date":358,"type":83},"2025-01-17",{"date":360,"type":83},"2021-12-30",{"date":362,"type":20},"2041-12-30",{"name":188,"class":90},{"id":365,"slug":366,"hasResults":11,"nctId":367,"briefTitle":368,"officialTitle":369,"acronym":4,"eligibilityCriteria":370,"healthyVolunteers":11,"sex":16,"minAge":371,"maxAge":4,"enrollmentInfo":372,"targetDuration":4,"studyType":21,"phases":374,"briefSummary":375,"conditions":376,"keywords":381,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":384,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":390,"locationsCount":392},"100490656","phase-2-restor-i-131-upt--selpercatinib-in-ret-f-p-rai-r-tc-100490656","NCT05668962","Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC","Restoration of Radioiodine Uptake with Selpercatinib in RET Fusion-Positive Radioiodine-Refractory Thyroid Cancer: a Phase 2 Study Performed in Collaboration with the International Thyroid Oncology Group (ITOG)","Inclusion Criteria:\n\n* Participants must have histologically- or cytologically-confirmed follicular-derived nonanaplastic thyroid cancer that is metastatic and\u002For unresectable AND harbors a known oncogenic RET gene fusion, performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified or equivalently accredited diagnostic laboratory.\n* Tumor tissue or liquid biopsy-based next-generation sequencing (NGS), quantitative polymerase chain reaction (qPCR), and fluorescence in situ hybridization (FISH) for RET gene fusion detection will be permitted.\n* Participants ≥ 18 years of age must have measurable disease, per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.\n\n  \\-- Participants 12 to \\\u003C18 years of age may enroll with either evaluable (i.e. anatomically visible tumor on cross sectional imaging, but tumors do not need to be \\>1 cm) or measurable disease per RECIST v1.1.\n* Participants should have no single tumor deposit exceeding 4.0 cm in the greatest dimension.\n* Participants must have RAI-refractory disease, as defined by:\n\n  * The malignant tissue does not concentrate RAI on a whole body scan following radioiodine administration\n  * The tumor tissue has lost the ability to concentrate RAI on a whole body scan following radioiodine administration after previous evidence of uptake at any earlier timepoint,\n  * RAI is taken up in some but not all tumor deposits on a whole body scan following radioiodine administration and\u002For\n  * There is progressive disease per RECIST v1.1 despite RAI uptake on a whole body scan following radioiodine administration and\u002For\n  * For patients 12 to \\\u003C18 years of age, there is persistent anatomically visible tumor on cross sectional imaging following prior therapeutic radioiodine administration\n* Participants may have received no more than a total cumulative RAI dose for treatment (not including RAI given for diagnostic purposes only) of 500 mCi (18.5 GBq).\n* Participants must have asymptomatic or minimally symptomatic disease, as judged by the treating investigator. For example, patients with bone metastasis associated with mild pain not requiring narcotics for pain control, or patients with lung metastasis associated with mild cough that does not limit the participant's activities, may be considered minimally symptomatic. If confirmation of this criterion is needed, discussion with the protocol chairperson is required prior to enrollment.\n* Prior external beam radiotherapy is allowed. For participants with disease limited to a prior radiotherapy field, this must be considered measurable per RECIST v1.1.\n* Participants may have had no more than one prior systemic therapy for RAI-refractory thyroid cancer, including lenvatinib, sorafenib, or other MKIs. This also includes chemotherapy and\u002For targeted therapy administered within a clinical trial, but does not include I-131 NaI or levothyroxine. Prior RET-specific kinase inhibitor therapy, such as selpercatinib and pralsetinib, is not allowed.\n* At least 28 days must have passed since any prior radiation or major surgery. At least 28 days must have passed since any prior systemic therapy for thyroid cancer, excluding thyroid hormone replacement.\n* Participants must be ≥18 years of age. Patients as young as 12 years of age will be allowed if permitted by local regulatory authorities and institutional review boards.\n\n  \\-- All patients of 12 to \\\u003C 18 years of age will be asked to provide assent and the legally designated representative will be asked to provide written consent.\n* Participants ≥ 16 years of age must have an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1. Participants 12 to \\\u003C16 years of age must have a Lansky Performance Score of ≥ 60.\n* Participants must have a life expectancy greater than 12 months.\n* Participants must have the ability to swallow medications and have no gastrointestinal abnormality that may alter medication absorption.\n* Participants must have adequate organ and marrow function as defined below. Bloodwork must be collected within 7 days prior to Cycle 1 Day 1:\n\n  * leukocytes ≥3,000\u002FmcL\n  * absolute neutrophil count (ANC) ≥1,500\u002FmcL\n  * platelets ≥100,000\u002FmcL\n  * hemoglobin ≥9 g\u002FdL\n  * total bilirubin ≤ 1.5 × institutional upper limit of normal (ULN) OR \\\u003C3.0 x institutional ULN for participants with Gilbert syndrome\n  * AST(SGOT)\u002FALT(SGPT) ≤2.5 × institutional ULN OR ≤5 × institutional ULN if the liver has tumor involvement\n  * creatinine ≤ institutional ULN OR creatinine clearance ≥30 mL\u002Fmin\n* Participants must have serum potassium, calcium and magnesium levels within institutional range of normal (may be receiving supplements). Bloodwork must be collected within 7 days prior to Cycle 1 Day 1.\n* Known human immunodeficiency virus (HIV)-infected participants on effective anti- retroviral therapy with an undetectable viral load within 6 months are eligible for this trial.\n* For participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.\n* Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. For participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.\n* Participants with treated brain metastases are eligible if the patient is asymptomatic AND follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression.\n* Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. For example, participants with nonmelanoma skin cancer, carcinoma in situ of the cervix or malignancy diagnosed ≥2 years previously and not currently receiving anticancer treatment are eligible. Patients receiving adjuvant hormone therapy for breast or prostate cancer with no evidence of disease are eligible.\n* Participants with known history or current symptoms of cardiac disease or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants should be class 2B or better.\n* Selpercatinib may impair fertility in men and women. The effects of selpercatinib on the developing human fetus are unknown. For this reason and because selpercatinib as well as other therapeutic agents used in this trial may be teratogenic, women of child-bearing potential (WOCBP) and men must agree to use highly effective contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation and for 6 months after the last dose of study drug. Unless not allowed by local regulations, WOCBP who are abstinent (if this is complete abstinence, as their preferred and usual lifestyle) or in a same-sex relationship (as part of their preferred and usual lifestyle) must agree to either remain abstinent or stay in a same-sex relationship without sexual relations with males. Periodic abstinence (e.g. calendar, ovulation, symptothermal, postovulation methods), declaration of abstinence just for the duration of the trial, and withdrawal are not acceptable methods of contraception. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men with partners who are WOCBP must agree to use a highly effective contraceptive method during treatment with the study drugs and for 6 months following the last dose of study drug.\n* WOCBP must have a negative pregnancy test (serum or urine) within 7 days prior to initiating study treatment, and not be breast-feeding within two months prior to study entry, during treatment, and for ≥1 week after the last dose of study therapy.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Participants who have had chemotherapy, MKI or radiotherapy within 4 weeks.\n* Participants who have had I-131 NaI treatment within 12 months.\n* Participants who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \\> Grade 1) with the exception of alopecia.\n* Participants who are receiving any other investigational agents.\n* Participants with symptomatic CNS metastasis or lesions threatening for spinal cord compression are not eligible.\n* Participants with clinically significant active cardiovascular disease or history of Torsades de pointes, history of myocardial infarction within 6 months prior to planned start of study treatment, or prolongation of the corrected QT interval by Fridericia's formula (QTcF) \\>470 msec on more than one ECG during Screening. Correction of suspected drug-induced QTcF prolongation may be attempted at the investigator's discretion if clinically safe to do so.\n* Participants with uncontrolled hypertension at screening, as defined by \\>160\u002F95 mm Hg.\n* Participants with uncontrolled hypertension at screening may be re-screened after appropriate medical therapy for hypertension.\n* Participants with an active uncontrolled systemic bacterial, viral, or fungal infection or serious ongoing intercurrent illness, such as hypertension or diabetes, despite optimal treatment, a clinical diagnosis or symptoms of interstitial lung disease, or other serious medical conditions which in the medical judgment of the investigator would prevent the patient from safely participating (screening for chronic conditions is not required).\n* Participants with uncontrolled symptomatic hyperthyroidism or hypothyroidism.\n* Participants with symptomatic hypercalcemia or hypocalcemia.\n* Participants with active hemorrhage or at significant risk for hemorrhage.\n* Participants who are taking a concomitant medication that is known to cause QTc prolongation ).\n* Participants with clinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal absorption of the drug.\n* Participants with other uncontrolled serous intercurrent illness that would interfere with the ability to proceed with study therapy.","12 Years",{"count":373,"type":20},30,[24],"This research is being done to determine the efficacy of selpercatinib to restore radioactive iodine (I-131 NaI) uptake and allow for I-131 treatment in people with RET fusion-positive radioiodine-refractory thyroid cancer.\n\nThis research study involves the study drug selpercatinib in combination with standard of care treatments, I-131 and thyrotropin alfa (rhTSH).",[46,47,377,378,379,380],"Metastatic Thyroid Cancer","Follicular Thyroid Cancer","Unresectable Thyroid Gland Carcinoma","Papillary Thyroid Cancer",[46,47,377,378,379,382],"Papillary thyroid cancer","2024-12-07",{"date":385,"type":83},"2024-12-12",{"date":387,"type":83},"2023-03-01",{"date":389,"type":20},"2026-01-01",{"name":391,"class":90},"Massachusetts General Hospital",6,{"id":394,"slug":395,"hasResults":11,"nctId":396,"briefTitle":397,"officialTitle":398,"acronym":4,"eligibilityCriteria":399,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":400,"enrollmentInfo":401,"targetDuration":4,"studyType":21,"phases":403,"briefSummary":404,"conditions":405,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":410,"completionDateStruct":411,"leadSponsor":413,"locationsCount":139},"100413631","function-integrity-of-neck-anatomy-in-thyroid-surgery-100413631","NCT04666103","Function Integrity of Neck Anatomy in Thyroid Surgery","Preserving Function Integrity of Neck Anatomy in Thyroid Surgery: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Patients diagnosed with unilateral thyroid carcinoma and contralateral benign nodule confirmed by preoperative ultrasound-guided fine-needle aspiration cytology;\n* Patients with contralateral nodules ≤ 20mm and located in the thyroid gland;\n* Patients with clinical node-negative cervical compartment at palpation and neck ultrasound.\n\nExclusion Criteria:\n\n* Previous history of neck surgery\n* Previous history of neck radiation therapy","75 Years",{"count":402,"type":20},1264,[101],"Recent trends in the management of patients with low-risk papillary thyroid carcinoma who have a nonsuspicious or cytologically benign contralateral nodule call into question the need for routine total thyroidectomy. Although the lobectomy for the unilateral thyroid cancer with contralateral benign nodules is sufficient treatment, some of the patients might suffer from the anxiety of the residual benign thyroid nodule and tend to choose total thyroidectomy, which might be overtreatment.\n\nThermal ablation has been proven to be effective in achieving nodule shrinkage and being also free from major complications. In our institution, intraoperative RFA was a proposed alternative strategy to treat the contralateral benign nodules after the thyroid lobectomy for the malignant lobe, which was found to have a better quality of life on anxiety, physiological health, social family, psychological and sensory mentions with a considerable complication rate.",[47,355,406],"Ablation; Retina","2020-12-11",{"date":409,"type":83},"2020-12-14",{"date":407,"type":83},{"date":412,"type":20},"2026-12-12",{"name":414,"class":90},"Wuhan University"]